Stock VSBC VITASPRING BIOMEDICAL CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials VitaSpring Biomedical Co. Ltd.

Equities

VSBC

US92851B1026

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 14:03:41 2023-08-11 EDT 		5-day change 1st Jan Change
15 USD +36.24% Intraday chart for VitaSpring Biomedical Co. Ltd. -.--% -.--%
2022 VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022 CI
2022 VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022 CI

Valuation

Fiscal Period: Januar 2020 2021 2022
Capitalization 1 22.89 728.8 2,891
Enterprise Value (EV) 1 22.89 728.8 2,892
P/E ratio 3,333 x -2,570 x 2,282 x
Yield - - -
Capitalization / Revenue 1,512,167,239 x 2,936,352,135 x 515,085,944 x
EV / Revenue 1,512,167,239 x 2,936,169,226 x 515,149,430 x
EV / EBITDA -1,202,679,765 x -1,717,705,573 x 1,938,319,108 x
EV / FCF - - -9,115,958,651 x
FCF Yield - - -0%
Price to Book - 26,144 x 1,833 x
Nbr of stocks (in thousands) 54,510 60,734 206,520
Reference price 2 0.4200 12.00 14.00
Announcement Date 6/9/20 4/14/21 5/3/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Januar 2017 2018 2019 2020 2021 2022
Net sales - 0.0162 0.0172 0.0151 0.2482 5.613
EBITDA - -0.005408 -0.0209 -0.019 -0.4243 1.492
EBIT - -0.005783 -0.0213 -0.0195 -0.4247 1.483
Operating Margin - -35.63% -124.18% -128.71% -171.12% 26.43%
Earnings before Tax (EBT) 1 -0.000108 -0.006374 -0.0224 0.006919 -0.4254 1.481
Net income 1 -0.000108 -0.006374 -0.0224 0.006919 -0.4254 1.264
Net margin - -39.27% -130.36% 45.7% -171.39% 22.52%
EPS - -0.000141 -0.000456 0.000126 -0.004669 0.006136
Free Cash Flow - 0.000912 -0.0252 - - -0.3172
FCF margin - 5.62% -146.6% - - -5.65%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/6/17 5/16/18 4/26/19 6/9/20 4/14/21 5/3/22
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Januar 2017 2018 2019 2020 2021 2022
Net Debt 1 0 0 0.02 - - 0.36
Net Cash position 1 - - - - 0.05 -
Leverage (Debt/EBITDA) - -0.5349 x -0.8736 x - - 0.2389 x
Free Cash Flow - 0 -0.03 - - -0.32
ROE (net income / shareholders' equity) - 2,747% 433% -200% -883% 151%
ROA (Net income/ Total Assets) - -41.4% -110% - - 48.9%
Assets 1 - 0.0154 0.0204 - - 2.586
Book Value Per Share 2 0 -0 -0 - 0 0.0100
Cash Flow per Share 2 0 0 0 - 0 0
Capex - 0 - - - 0.07
Capex / Sales - 13.86% - - - 1.3%
Announcement Date 3/6/17 5/16/18 4/26/19 6/9/20 4/14/21 5/3/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VITASPRING BIOMEDICAL CO. LTD. Stock VitaSpring Biomedical Co. Ltd.
-.--% 3.11B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.44% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.94% 113B
ARGENX SE Stock argenx SE
+18.54% 26.22B
BIONTECH SE Stock BioNTech SE
-25.37% 19.01B
GENMAB A/S Stock Genmab A/S
-19.81% 15.71B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.20% 15.22B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.37% 14.72B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+59.91% 14.58B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.35% 13.84B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VSBC Stock
  4. Financials VitaSpring Biomedical Co. Ltd.